Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efavaleukin alfa in moderately to severely active ulcerative colitis
NCT04987307Phase 2Terminated
- Sponsor
- Amgen
- Start
- Jan 2022
- Primary completion
- Oct 2024
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 26
01
Overview
A Phase 2 trial of efavaleukin alfa in ulcerative colitis (UC), sponsored by Amgen. Started Jan 2022; status: terminated.
02
Drugs
efavaleukin alfa
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04987307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04987307.